Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05512208 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Study acronym: DURAFAK
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 4
    • Eligibility criteria expanded, about 7 words
    v8
  2. Study sites: 2 to 3
    • Eligibility criteria expanded, about 4 words
    v7
  3. Study sites: 1 to 2v6
  4. 2 versions Re-verified since Nov 8, 2023, no change to tracked fieldsv4-v5
  5. Interventions: VS-6766 + defactinib (Drug) to Avutometinib (VS-6766) + defactinib (Drug)
    • Secondary endpoints: details revised at 2 of 5 entries
    • Study title expanded, about 1 word
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2022 to Feb 6, 2023
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Trial Details
NCT Number NCT05512208
Lead Sponsor University of Oklahoma
Collaborators: Verastem, Inc.
Conditions
(from sponsor)		 Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer, Solid Tumor
Related terms Uterine Cervical Neoplasms
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov